dna-istock-518143098-ralwel--2
ralwel / iStockphoto.com
13 July 2018BiotechJakob Wested, Timo Minssen, Esther van Zimmeren

Will the EPO’s Enlarged Board hear the Broad’s CRISPR case?

“The Opposition Division’s interpretation of the European Patent Convention (EPC) is inconsistent with treaties designed to harmonise the international patent process, including that of the US and Europe.” This was the rather strong reaction of the Broad Institute (BI) after the European Patent Office’s (EPO) Opposition Division’s (OD) decision to revoke one of its CRISPR patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
23 October 2026   Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.
Biotech
16 October 2026   All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.
Biotech
29 September 2026   The gene-editing company has accused a former employee of secretly co-founding a Chinese biotech while still at the company, in a trade secrets lawsuit involving rival base-editing therapies and disputed patent filings.